Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
InflaRx Profile | The Scientist
InflaRx Reports Full Year 2023 Results and Announces INF904 Development ...
Inflarx (IFRX) Investor Presentation - Slideshow (NASDAQ:IFRX ...
Börse Express - InflaRx Aktie: Explosiver Ritt auf der Achterbahn
InflaRx N.V. Prognose 2026 & Kursziel von Analysten
Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7%
InflaRx N.V. (IFRX) Stock Price, Quote, News & Analysis | Seeking Alpha
InflaRx N.V.
InflaRx Aktie: Entscheidende Wochen! | Börse Express
InflaRx N.V. (IFRX) News, Articles, Events & Latest Updates
InflaRx Aktie: Strategische Wende mit Risiken
InflaRX jumps 60% On FDA emergency approval of Gohibic for Covid-19 ...
InflaRx aus Jena sammelt weitere $ 117 Mio. an der NASDAQ ein, bm-t ...
InflaRx anuncia una profunda reestructuración, con despidos del 30% de ...
InflaRx N.V. - InflaRx - virtual R&D event INF904: oral C5aR inhibitor ...
InflaRx N.V. - AnnualReports.com
InflaRx | The Org
InflaRx Aktie: Was treibt den Kurs der Aktie?
InflaRx will attend the upcoming EADV Congress, one of the leading ...
InflaRx to Reveal Phase 2a Clinical Trial Data Amid Q3 2025 Financials
INFLARX N.V.-Aktie mit neuem 6-Monats-Hoch - boerse.de
InflaRx regains Nasdaq compliance after shares trade above $1
InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price ...
InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in ...
Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation
InflaRx Aktie News | aktuelle Nachrichten | A2H7A5 | NL0012661870 ...
Inflarx N.V. (IFRX) Análisis de matriz Ansoff – DCFmodeling.com
Why InflaRx N.V. Stock Is Poised For A Rebound?
𝐈𝐧𝐟𝐥𝐚𝐑𝐱 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐅𝐮𝐥𝐥 𝐘𝐞𝐚𝐫 2024 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐚𝐧𝐝… | InflaRx
InflaRx nach Kursexplosion: Kapitalerhöhung – die Details - DER AKTIONÄR
Exploring InflaRx N.V. (IFRX): Who s Buying and Why? – DCFmodeling.com
InflaRx Prepares for Key Phase 2a Clinical Trial Results
InflaRx Set to Reveal 2024 Results and Join Investor Events - Investors ...
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
InflaRx to Announce Phase 2a INF904 Data in HS and CSU Nov 10 | IFRX ...
InflaRx Ends Lead Asset Development After Failed Study For Rare And ...
The InflaRx N.V. team got finally rewarded for their relentless work ...
Buy InflaRx Stock – IFRX Stock Quote Today & Investment Insights ...
Guggenheim Upgrades InflaRx N.V. (IFRX) | Nasdaq
InflaRx NV美股招股说明书(2025-02-13版)
InflaRx today announced that the Company will publish its financial and ...
IFRX - InflaRx | Fundamentei
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with ...
InflaRx Announces Decision to Enter Phase III Development of IFX‑1 in ...
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
InflaRx COVID injection gets US FDA's emergency-use authorization, ET ...
InflaRx on LinkedIn: Today, we announced our Q3 results and shared our ...
InflaRx on LinkedIn: We are excited to announce positive topline ...
Is InflaRx NV Gaining or Losing Market Support? - InflaRx (NASDAQ:IFRX ...
InflaRx Aktie: Explosiver Anstieg!
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS ...
We are proud to announce The InflaRx Commitment Program for GOHIBIC ...
InflaRx Gets Nasdaq Notice Over $1 Minimum Bid Price Requirement | IFRX ...
InflaRx N.V. on LinkedIn: Today, we hosted an R&D event to highlight ...
InflaRx Advances INF904 for CSU and HS with Phase 2a Study ...
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 ...
InflaRx Is Not Worth Chasing Following Emergency Use Authorization ...
InflaRx is strongly undervalued : r/ifrx
InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions
InflaRx Navigates Clinical Crossroads: Can Upcoming Data Turn the Tide?
InflaRx on LinkedIn: #inflarx #bioeurope2023 #vilobelimab
InflaRx on LinkedIn: #gohibic #vilobelimab
InflaRx N.V. on LinkedIn: #inf904
IFRX | InflaRx Submits Request for Emergency Use Authorization to US ...
#iddst #complement #inflammation #c5a #iddst2024 | InflaRx
InflaRx Announces Top-Line SHINE Phase IIb Results for
InflaRx stock crashes on study failure in HS - QuotedData
InflaRx N.V. (IFRX): Business Model Canvas – DCFmodeling.com
InflaRx N.V. (IFRX) BCG Matrix Analysis – DCFmodeling.com
Jenaer Biotech-Firma InflaRx schafft Sprung an die NASDAQ - Jena TV ...
Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform ...
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why | Nasdaq
Finanznachrichten & Börsen-News | Börse Express
Press Releases
InflaRx, a bm|t Investee-Partner, completed a minimum 75 Mio. USD ...
InflaRx-Aktie vorbörslich im freien Fall – Studienabbruch schockt ...
InflaRx'in dördüncü çeyrek zararı beklentilerin altında - Midas
Reining in Inflammation to Treat ARDS | The Scientist
Companies Financial Statements
INFLARX-AKTIE kaufen? Analysen, Kursziele & Empfehlungen zu A2H7A5
#nielsriedemann #inflarx #inflammation #complementcomponent5a #sepsis ...
Jun Hu on LinkedIn: WuXi Biologics Announces Manufacturing Partnership ...
InflaRx’s Sudden 14% Drop: What’s Behind the Sharp Intraday Slide?
C5a抗体获批治疗重症新冠，InflaRx股价大涨84%，舒泰神拥有中国权益医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
At the 9th Annual Complement-Based Drug Development Summit in Boston ...
inflarx.sharepoint.com - Sign in to your account
【藥明2269】藥明生物與德藥廠InflaRx合作 加速推進新冠重症藥Gohibic
Home [www.inflarx.de]
InflaRx’s Anticipated Phase 2a Results Could Catalyze Stock Rally
Sponsors and Supporters — World Sepsis Day - September 13
Deutsche Biotech-Hoffnung InflaRx: Aktie explodiert nach Daten – die ...
Home - ARDSAlliance.org
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
